01—Abstract
Summary
Summary of the 10-K filed March 3, 2004. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' 2003 10-K shows a company that grew revenue 15% to $476.0 milliona and net income 26% to $57.1 million (diluted EPS $1.59, up from $1.30).
Growth was led by the Companion Animal Group (CAG), which rose 18% to $384.4 millionb on strong LaserCyte hematology instrument sales, rapid assays, and laboratory services. Operating income rose 22% to $80.4 million, and operating margin widened to 16.9% from 15.9%, helped by a higher gross margin of 48.4%. Part of the growth reflects a favorable comparison with 2002, when distributor inventories were reduced, and about 4 points of revenue growth came from currency effects.
The balance sheet strengthened, with cash and investments of $255.8 millionc and debt of only $0.5 million. Operating cash flow reached $117.2 million, and the company repurchased about $36 million of stock. Management also flagged risks, including a $7.4 million non-cash write-down tied to ending development of an alternative chemistry analyzer after a new supply agreement with Ortho, a dependence on Ortho for VetTest slide purchases with minimum commitments of $170.4 million through 2010, and rising heartworm test competition as rivals re-entered the market.
The company also disclosed a litigation dispute with its computed radiography supplier, though it said it is not party to any material legal proceedings. For investors, the key questions are whether the instrument and laboratory growth can be sustained, whether competition in heartworm testing erodes rapid assay pricing, and whether the Ortho dependency and the pipeline of pharmaceutical products (NAVIGATOR approved in November 2003) can diversify the revenue base over time.
02—Key points
Key Highlights
- Revenue rose 15.3% to $476.0M; CAG (81% of sales) grew 17.6% to $384.4M, driven by the LaserCyte hematology system launched in late 2002 (instrument sales up ~127%).
- Operating income rose 22.1% to $80.4M, with operating margin expanding to 16.9% from 15.9%; gross margin improved to 48.4% from 46.7%.
- Net income grew 25.8% to $57.1M; diluted EPS was $1.59 vs. $1.30, and the effective tax rate fell to 31.5% from 34.0%.
- Strong liquidity: $255.8M in cash and investments, $0.5M total debt, and $117.2M operating cash flow; $36.2M used for share repurchases in 2003.
- A $7.4M non-cash write-down reduced 2003 results after IDEXX ended development of an alternative clinical chemistry analyzer in favor of a next-generation instrument with Ortho (slide supply extended through 2018).
- Heartworm competition is intensifying as a competitor re-entered the market in January 2004 and another entered, which could pressure rapid assay growth in 2004.
- Dependence on single sources, including Ortho for VetTest slides ($170.4M minimum purchases through 2010) and Becton Dickinson for QBC analyzers, along with an active supplier lawsuit over computed radiography systems.
03—Questions
Frequently Asked Questions
What drove IDEXX's revenue and earnings growth in 2003?
Revenue grew 15% to $476.0M, led by the Companion Animal Group, which rose 18% on LaserCyte hematology instrument sales, rapid assays (canine heartworm and FIV/FeLV tests), instrument consumables, and laboratory services. Net income grew 26% to $57.1M, aided by gross margin expansion and a lower effective tax rate. Some of the growth reflects easy comparisons against 2002, when distributor inventories were reduced, and currency tailwinds contributed roughly 4 points of growth.
How strong is IDEXX's balance sheet and cash generation?
The company ended 2003 with $255.8M in cash and investments and only $0.5M in notes payable, against $413.3M of stockholders' equity. Operating cash flow was $117.2M, up from $103.3M in 2002. Capital expenditures were $16.9M, and the company repurchased about $36.2M of stock in 2003, with a 2004 capital budget of about $23.0M.
What are the main risks to IDEXX's growth outlook?
Key risks include rising heartworm test competition as rivals re-enter the market; reliance on Ortho for VetTest slides, with a $170.4M minimum purchase commitment through 2010 and fixed slide pricing; regulatory approval timing for new pharmaceuticals and the diclofenac and tilmicosin pipeline; and a supplier lawsuit over computed radiography systems that could cut off supply or lead to damages. The company also depends on distributor purchasing patterns, which can distort reported quarterly results.
Did IDEXX have any significant one-time charges or write-downs in 2003?
Yes. In Q4 2003 IDEXX recorded a non-cash pre-tax charge of about $7.4M to write down manufacturing equipment for an alternative chemistry analyzer after it entered the new Ortho agreement and discontinued that development. It also recorded a $0.1M charge tied to the 2002 CEO succession agreement. Management said the write-down reduced net income by $7.4M, and the company expects to realize its remaining LaserCyte inventory of $7.2M plus $3.5M in purchase commitments.
Is IDEXX dependent on any single customer or geography?
No single customer accounted for more than 10% of 2003 sales, though the company's largest customers are CAG distributors. International revenue was 30% of total sales in 2003, up from 28% in 2001, with the U.S. representing about 70%. Production animal diagnostics were about 70% international, which makes FDG particularly exposed to foreign regulatory and currency risks.
04—Continue